ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,562.45
4.96%
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs Yen
156.219
0.29%
Brent Oil
83.535
-0.07%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. イギリス
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) ニュース

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
から:
次の項目別のソート:
 Showing the most relevant articles for your search:LSE:HCM
日付受信時刻ニュースソース見出しコード企業名
2024/05/1801 : 58Alliance NewsAlliance NewsIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan EldarLSE:HCMHutchmed (china) Limited
2024/05/1723 : 00RNS Regulatory NewsHutchmed (China) Limited Retirement of Chairman and new Chairman appointedLSE:HCMHutchmed (china) Limited
2024/05/1715 : 00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Data to be Presented at EHA2024 CongressLSE:HCMHutchmed (china) Limited
2024/05/1422 : 33Alliance NewsAlliance NewsHutchmed announces trials of HMPL-306 and Surufatinib cancer therapiesLSE:HCMHutchmed (china) Limited
2024/05/1415 : 00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Registrational Phase III TrialLSE:HCMHutchmed (china) Limited
2024/05/1415 : 00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase II/III Trial with HengruiLSE:HCMHutchmed (china) Limited
2024/05/1021 : 00RNS Regulatory NewsHutchmed (China) Limited Result of AGMLSE:HCMHutchmed (china) Limited
2024/05/0817 : 30RNS Regulatory NewsHutchmed (China) Limited Directorate ChangeLSE:HCMHutchmed (china) Limited
2024/04/2700 : 09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
2024/04/2621 : 30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
2024/04/2217 : 30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
2024/04/0817 : 30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
2024/04/0517 : 30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
2024/04/0218 : 32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
2024/04/0215 : 00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
2024/03/2820 : 08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
2024/03/2816 : 00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
2024/03/2219 : 09Alliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
2024/03/2216 : 16Alliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
2024/03/2216 : 00RNS Non-RegulatoryHutchmed (China) Limited Initiation of Registration Stage of P2/3 TrialLSE:HCMHutchmed (china) Limited
2024/03/1418 : 00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
2024/03/0517 : 30RNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
2024/02/2902 : 31Alliance NewsAlliance NewsEARNINGS: Hutchmed revenue surges, Craven House's loss widensLSE:HCMHutchmed (china) Limited
2024/02/2821 : 45RNS Non-RegulatoryHutchmed (China) Limited Publication of Form 20-FLSE:HCMHutchmed (china) Limited
2024/02/2820 : 30RNS Regulatory NewsHutchmed (China) Limited 2023 Full Year Results and Business UpdatesLSE:HCMHutchmed (china) Limited
2024/02/0718 : 50Alliance NewsAlliance NewsHutchmed hails fruquintinib trial results for gastric cancer treatmentLSE:HCMHutchmed (china) Limited
2024/02/0716 : 00RNS Non-RegulatoryHutchmed (China) Limited Presentation of Phase III Data on FruquintinibLSE:HCMHutchmed (china) Limited
2024/02/0218 : 52Alliance NewsAlliance NewsHutchmed says Inmagene exercises option to licence drug candidatesLSE:HCMHutchmed (china) Limited
2024/02/0217 : 37RNS Non-RegulatoryHutchmed (China) Limited Inmagene Exercises Option for Two Drug CandidatesLSE:HCMHutchmed (china) Limited
2024/02/0117 : 30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2023 Final ResultsLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

最近閲覧した銘柄

EU
BQPEQ
La Banque Postale Home L...
LSE
95JU
Anz Bank
LSE
QL07
Morg.st.b.v 25
USOTC
BCCMY
BAIC MTR (PK)
NYSE
KVUE
Kenvue
BIT
P1VGM9
NLBNPIT1VGM9 20991231 64...
BIT
F22666
Vontobel Financial Produ...
LSE
0R4P
Lifco Ab (publ)
BIT
UIB888
Unicredit Bank
EU
AFRHG
Amundi Luxembourg
LSE
QJ86
Morg.st.b.v 24
EU
3072T
3072T
LSE
60CE
Malmo 24
BIT
Q00343
Leonteq Securities
BIT
P1ZG70
NLBNPIT1ZG70 20241220 35
USOTC
BNOW
BOON Industries (PK)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有